Resultado de búsqueda
22 de may. de 2024 · One of the most controversial aspects in historical analysis is the existence or non-existence in archaic times, of a supposed ius migrandi.On it, in fact, is polarized and the dichotomy between those who describe an overall situation of great juridical commonality, as well as ethnic, in the light of which Rome stands out as a community aimed at inclusion and those who, while not expressly ...
Hace 21 horas · TV MasterChef, Samantha Vallejo-Nágera y lo nunca visto. "Vergüenza", "vergüenza" y más "vergüenza". Esta fue la palabra más repetida anoche en MasterChef 12. Recordaba a aquella escena de ...
Hace 21 horas · In the United States alone, the prevalence of MASH is projected to increase from approximately 16.5 million in 2015 to 27.0 million in 2030. In the absence of changes in diet and exercise, the inflammation inherent in MASH persists and may result in progressive fibrosis of the liver, which may result in cirrhosis.
Hace 3 horas · HERALD ( NCT06342947) is a randomized, double-blind, placebo-controlled trial that has enrolled approximately 100 subjects with presumed MASH and stage 1-3 liver fibrosis (F1-F3). Subjects were randomized to receive one of four doses (0.3, 0.5, 0.7, 0.9 mg) of ALG-055009 or placebo (~20 subjects/arm) given orally once daily for 12 weeks. The ...
Hace 9 horas · Topline data now projected in early Q4 2024 Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing
Hace 21 horas · Generative AI can help by introducing real-time intent recognition. When a shift in intent occurs, the technology can adjust the interaction dynamically. Generative AI can automatically summarize ongoing interactions, capturing critical details, intents, and customer actions. When a customer’s call is transferred, the technology can provide ...
Hace 21 horas · Topline data now projected in early Q4 2024 Rohit Loomba, MD, MHSc to serve as Principal Investigator Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company ...
